Quick Answer
Kyverna Therapeutics, Inc. reported Research And Development Expense of $133.72 million for the year ending 2025.
- Kyverna Therapeutics, Inc. showed an increase of +18.9% in Research And Development Expense from 2024 to 2025.
- This data is from Kyverna Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $8.71 million | Q2 2023: $10.41 million | Q3 2023: $13.64 million | Q1 2024: $22.48 million | Q2 2024: $27.32 million | Q3 2024: $29.19 million | Q1 2025: $37.43 million | Q2 2025: $35.82 million | Q3 2025: $30.46 million.
- Over the full 3 years of available data (2023 to 2025), Kyverna Therapeutics, Inc.'s Research And Development Expense has grown by 167.9%.
- Historical annual values: Fiscal year 2025: $133.72 million | Fiscal year 2024: $112.47 million | Fiscal year 2023: $49.92 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: